High-throughput epigenetic profiling made possible in single cells with ICELL8® technology

MOUNTAIN VIEW, Calif., March 18, 2019 /PRNewswire/ -- Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., is proud to announce that researchers from Steven Henikoff's laboratory (Fred Hutchinson Cancer Research Center) have developed a novel epigenomic method, CUT&Tag (Cleavage Under Targets and Tagmentation), for high-throughput profiling of chromatin components in single cells on the ICELL8 Single-Cell System.

This new method meets the growing needs of the high-throughput single-cell research community for tools that can survey regulatory information in genomes. Taking advantage of the ICELL8 system's gentle dispensing and imaging capabilities, the researchers were able to develop the protocol on cells that were permeabilized and pretreated with antibodies. Additionally, the ability to individually index single cells via the SmartChip™ array simplified their process for single-cell analysis which would otherwise have required individually barcoded Tn5 complexes.

"Seeing researchers develop new methods on the ICELL8 system has been very fulfilling," said Carol Lou, President of Takara Bio USA, Inc. "We are proud to have an open platform that enables scientists to develop their own powerful high-throughput applications, like CUT&Tag. This application is particularly exciting to us because it brings the power of single-cell analysis to a research area where it had previously been technically challenging."

About Takara Bio

Takara Bio USA, Inc. (TBUSA; formerly Clontech Laboratories, Inc.) is a wholly owned subsidiary of Takara Bio Inc. that manufactures and distributes kits, reagents, and instruments for life sciences research applications, including NGS, PCR, gene delivery, genome editing, stem cell research, nucleic acid and protein purification, and automated sample preparation.

SOURCE Takara Bio USA, Inc.

Related Links

http://www.clontech.com